Skip to content
Clinical Trials – home

Tamoxifen Citrate: A Comprehensive Guide for Patients

Tamoxifen Citrate is an investigational medicinal product. No trial currently registered in Europe lists it – that can change as new trials are authorised, and it may be under study elsewhere.

In short

Tamoxifen Citrate, a widely used medication in cancer treatment, is being studied in various clinical trials to explore its potential benefits in different medical conditions. This article summarizes key findings from recent clinical trials investigating the use of Tamoxifen Citrate in treating bladder tumors, oesophageal cancer, breast cancer, and other conditions. We'll explore the drug's mechanisms, potential benefits, and ongoing research efforts to expand its therapeutic applications.

What is Tamoxifen Citrate?

Tamoxifen Citrate is a medication widely used in the treatment of certain types of breast cancer. It belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). Tamoxifen Citrate is also known by several other names, including Nolvadex, Soltamox, and simply Tamoxifen. This medication has been in use for over 30 years and has helped millions of women in their fight against breast cancer.

Uses of Tamoxifen Citrate

Tamoxifen Citrate is primarily used in the treatment and prevention of breast cancer. Its main applications include:

  • Treatment of Breast Cancer: It is used to treat various stages of breast cancer, including early-stage, advanced, and metastatic (cancer that has spread to other parts of the body) breast cancer.
  • Prevention of Breast Cancer Recurrence: In women who have already been treated for breast cancer, Tamoxifen can help prevent the cancer from coming back.
  • Breast Cancer Prevention: In some cases, Tamoxifen may be prescribed to women at high risk of developing breast cancer to reduce their chances of getting the disease.
  • Treatment of Ductal Carcinoma In Situ (DCIS): This is a non-invasive type of breast cancer.

Interestingly, Tamoxifen is also being studied for its potential use in other conditions. For example, it's being investigated for the treatment of bladder cancer and esophageal cancer. Additionally, it has been used in fertility treatments to induce ovulation in women with polycystic ovary syndrome (PCOS).

How Tamoxifen Citrate Works

Tamoxifen Citrate works by blocking the effects of estrogen in breast tissue. Many breast cancers are stimulated to grow by estrogen, a hormone naturally produced in the body. These types of breast cancers are called estrogen receptor-positive (ER-positive) breast cancers.

By blocking estrogen's effects, Tamoxifen can:

  • Slow or stop the growth of existing breast cancer cells
  • Prevent cancer cells from dividing and multiplying
  • Reduce the risk of cancer developing in unaffected breast tissue

It's important to note that Tamoxifen is most effective in treating hormone receptor-positive breast cancers. These are cancers whose cells have receptors for estrogen (ER-positive) and/or progesterone (PR-positive).

How Tamoxifen Citrate is Administered

Tamoxifen Citrate is typically taken orally in the form of tablets. The dosage and duration of treatment can vary depending on the specific condition being treated and individual patient factors. Some common regimens include:

  • For breast cancer treatment: 20mg daily for 5 years or longer
  • For breast cancer prevention in high-risk women: 20mg daily for 5 years
  • For fertility treatment in PCOS: 10-20mg daily for 5 days, starting on the 3rd day of the menstrual cycle

It's crucial to take Tamoxifen exactly as prescribed by your doctor. The medication is typically taken for several years to get the full benefit.

Potential Side Effects

Like all medications, Tamoxifen can cause side effects. Common side effects may include:

  • Hot flashes
  • Nausea
  • Fatigue
  • Mood swings
  • Vaginal discharge or dryness
  • Irregular menstrual periods

More serious but less common side effects can include:

  • Blood clots
  • Stroke
  • Cataracts
  • Endometrial cancer (cancer of the uterine lining)

It's important to discuss any side effects with your healthcare provider.

Ongoing Research

Researchers continue to study Tamoxifen to understand its full potential and optimize its use. Some areas of ongoing research include:

  • Duration of Treatment: Studies are investigating whether shorter durations of Tamoxifen treatment (e.g., 2 years instead of 5) might be sufficient for some low-risk breast cancers.
  • Combination Therapies: Researchers are exploring how Tamoxifen works in combination with other drugs to improve its effectiveness.
  • Use in Other Cancers: As mentioned earlier, Tamoxifen is being studied for its potential in treating other types of cancer, such as bladder and esophageal cancer.
  • Personalized Medicine: Studies are looking at how genetic factors might influence a person's response to Tamoxifen, with the goal of tailoring treatment to individual patients.

Tamoxifen Citrate has been a cornerstone in breast cancer treatment for decades, and ongoing research continues to refine and expand its use. If you have any questions about Tamoxifen or its use in your treatment, don't hesitate to discuss them with your healthcare provider.

Questions people often ask

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).